Bruker Corporation $BRKR Stock Holdings Lessened by VELA Investment Management LLC

Key Points

• VELA Investment Management reduced its Bruker stake by 23% in the second quarter, selling 22,370 shares and retaining 74,924 shares valued at approximately $4.5 million. Institutional investors and hedge funds collectively own 79.52% of the company.
• Bruker reported quarterly EPS of $0.49, beating estimates by $0.11, while revenue rose 5.2% year over year to $838.5 million, below analyst expectations. The company maintained fiscal 2026 EPS guidance of $2.10–$2.15.
• Analyst sentiment is mixed, with a consensus “Hold” rating and a $56.64 target price; shares opened at $58.50. Bruker also declared a quarterly dividend of $0.05 per share, implying a 0.3% annualized yield.

VELA Investment Management LLC lowered its position in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 23.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 74,924 shares of the medical research company's stock after selling 22,370 shares during the period. VELA Investment Management LLC's holdings in Bruker were worth $4,509,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC bought a new stake in shares of Bruker in the 4th quarter worth approximately $26,000. Allworth Financial LP boosted its holdings in Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company's stock worth $29,000 after buying an additional 257 shares in the last quarter. Essential Partners LLC acquired a new position in Bruker in the first quarter worth approximately $36,000. Global Retirement Partners LLC acquired a new position in Bruker in the second quarter worth approximately $38,000. Finally, Parallel Advisors LLC increased its holdings in shares of Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company's stock valued at $41,000 after buying an additional 479 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Price Performance

BRKR opened at $58.50 on Tuesday. The firm has a market cap of $8.91 billion, a P/E ratio of -83.57, a price-to-earnings-growth ratio of 1.79 and a beta of 1.26. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85. The business has a 50 day moving average price of $58.73 and a 200 day moving average price of $48.87. Bruker Corporation has a twelve month low of $29.84 and a twelve month high of $65.30.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The business had revenue of $838.50 million during the quarter, compared to analysts' expectations of $853.57 million. During the same quarter in the previous year, the firm earned $0.32 EPS. The firm's revenue was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Research analysts forecast that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, September 21st. Bruker's dividend payout ratio (DPR) is presently -28.57%.

Analyst Upgrades and Downgrades

Several research analysts have commented on BRKR shares. Guggenheim raised their target price on shares of Bruker from $50.00 to $70.00 and gave the stock a "buy" rating in a report on Monday, June 29th. Weiss Ratings restated a "sell (d+)" rating on shares of Bruker in a research report on Monday, August 31st. Stifel Nicolaus set a $50.00 price objective on shares of Bruker in a research note on Wednesday, August 5th. Barclays lifted their price objective on shares of Bruker from $53.00 to $60.00 and gave the stock an "overweight" rating in a research report on Wednesday, June 24th. Finally, Wolfe Research initiated coverage on shares of Bruker in a research note on Monday, June 1st. They set a "peer perform" rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Bruker presently has a consensus rating of "Hold" and a consensus target price of $56.64.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.